3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
109
Endometrial Neoplasms
16
Neoplasm Metastasis
10
Polycystic Ovary Syndrome
9
Ovarian Neoplasms
7
Neoplasms
7
Advanced Breast Cancer
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Recurrence
3
Infertility
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Squamous Cell Carcinoma of Head and Neck
2
Progesterone Resistance
2
Neoplasms by Site
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Hyperplasia
2
Cystadenocarcinoma, Serous
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Breast Cancer Metastatic
2
Breast Cancer Female
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Fulvestrant
5
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
Paclitaxel
2
Letrozole
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
Alpelisib
2
venetoclax
1
tivozanib
1
tipifarnib
1
sotorasib
1
pembrolizumab
1
olaparib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
ceralasertib
1
cemiplimab
1
capivasertib
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Letrozole
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts